A Phase 1 interventional study of Nalbuphine HCl solution and Placebo solution in Nalbuphine and Opioid Abuse, sponsored by Trevi Therapeutics. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by Trevi Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.
Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 1, and was the 15th registered.
1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
Browse Opioid-Related Disorders studies →11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
Pouya Azar · Sites in Canada
Ages 19+
Eli Lilly and Company · Sites in Canada, United States, Puerto Rico and 1 more country
Ages 18–75
University of British Columbia · Sites in Canada
Ages 19–75
University of British Columbia · Sites in Canada
BC Centre on Substance Use · Sites in Canada
Ages 25+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 6 · Phase 4 9
First in 2005; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 51 across the 32 interventional studies, 260 across the 4 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 1 study filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Opioid-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT07546396Pouya AzarMethadone Rapid Restart | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Opioid-Related Disorders with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). The amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated.
This study has 2 parts: Part A and Part B.
This study will be a single-dose, randomized, double-blind, active- and placebo-controlled, double dummy, 2-part, 7-way crossover study to determine the abuse potential of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution and placebo, in non-dependent, recreational opioid users. The study will be conducted in a single clinical research unit (CRU).
The purpose of Part A is to find the appropriate doses (a low, intermediate, and high dose) of nalbuphine solution to use in Part B. Part A of the study has two visits to the research clinic: a screening visit and dose selection visit. The visits will involve a 2-night stay (3 days total) in the research clinic.
In the Main Study Treatment Phase in Part B, the total estimated duration between each dose of study drug is approximately up to 7 days, of which the subject will spend 3 days/2 nights in the research clinic and approximately up to 4 days at home.
The primary objective of the Main Study is to evaluate the abuse potential of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution (the active comparator) and placebo in non-dependent, recreational opioid users.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo 150 mL flavored beverage
Drug: Placebo solution
90 mg nalbuphine HCl solution 9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage
Drug: Nalbuphine HCl solution
120 mg nalbuphine HCl solution 12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage
Drug: Nalbuphine HCl solution
150 mg nalbuphine HCl solution 15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage
Drug: Nalbuphine HCl solution
180 mg nalbuphine HCl solution 18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage
Drug: Nalbuphine HCl solution
270 mg nalbuphine HCl solution 27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage
Drug: Nalbuphine HCl solution
Up to 405 mg nalbuphine HCl solution Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage
Drug: Nalbuphine HCl solution
Up to 540 mg nalbuphine HCl solution Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage
Drug: Nalbuphine HCl solution
nalbuphine solution administered at various strengths
Also known as: NAL ER
Placebo
To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).
Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max
Time frame: 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose
Only Part A of this study was completed. Treatment arms summarized are those that were used on in Part A.
| Milestone | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution |
|---|---|---|---|---|---|---|---|---|
| Started | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max
| microgram/L | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution |
|---|---|---|---|---|---|---|---|---|
| To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B). | — | 21.70 ± 6.65 | 51.90 ± 26.89 | 68.67 ± 30.19 | 76.60 ± 51.34 | 56.00 ± 6.09 | 158.55 ± 115.65 | 196.83 ± 92.34 |
Collected over 24 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| 90 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 120 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 150 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 180 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 270 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Up to 405 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Up to 540 mg Nalbuphine HCl Solution | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Age, Continuous(years) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.4 ± 8.3 | 38.5 ± 11.2 | 33.2 ± 7.3 | 31.0 ± 9.4 | 37.3 ± 13.6 | 34.8 ± 5.6 | 34.3 ± 11.9 | 42.5 ± 12.3 | 35.3 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 8 |
| Male | 14 | 3 | 3 | 5 | 5 | 6 | 6 | 6 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| Not Hispanic or Latino | 14 | 6 | 6 | 6 | 6 | 4 | 5 | 6 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 8 |
| White | 8 | 5 | 4 | 4 | 5 | 4 | 2 | 6 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 6 |
| Region of Enrollment(participants) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| Canada | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 56 |
| BMI(kg/m**2) | Placebo | 90 mg Nalbuphine HCl Solution | 120 mg Nalbuphine HCl Solution | 150 mg Nalbuphine HCl Solution | 180 mg Nalbuphine HCl Solution | 270 mg Nalbuphine HCl Solution | Up to 405 mg Nalbuphine HCl Solution | Up to 540 mg Nalbuphine HCl Solution | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 26.48 ± 3.45 | 26.17 ± 3.15 | 25.53 ± 4.04 | 23.48 ± 2.57 | 26.18 ± 4.39 | 25.43 ± 3.62 | 24.53 ± 3.17 | 22.32 ± 1.55 | 25.23 ± 3.44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Dec 2018, 6 months.
Results were first posted in Aug 2020, 1 year 8 months after primary completion.
Of 78 phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine